| Species Reactivity | Human |
| Clone | recibokibart |
| Source/Isotype | Human IgG1(K214R, L234A, L235A, D356E, L358M), Kappa |
| Application | / |
| Specificity | Detects IL-36R |
| Gene | IL-36R |
| Other Names | IL-1Rrp2, IL1RL2, IL1R-rp2, IL1RRP2 |
| Gene ID | 8808 (human) |
| Background | Recibokibart is a novel anti-IL-36R (interleukin-36 receptor) humanized monoclonal antibody that rapidly alleviates the inflammatory response by specifically blocking IL-36R activation and inhibiting downstream pro-inflammatory signaling pathways. It has shown rapid and long-lasting results in early clinical studies, improving skin symptoms significantly after a single dose and lasting for several weeks. Based on its unique mechanism of action, this drug has not only made breakthroughs in the treatment of specific types of psoriasis, but has also been found to have potential therapeutic value for other complex inflammatory skin diseases driven by neutrophils, and has been used in the treatment of psoriasis, especially in critically ill patients where traditional therapies have limited efficacy, the therapeutic promise of synergy is demonstrated. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | recibokibart |
| Source/Isotype | Human IgG1(K214R, L234A, L235A, D356E, L358M), Kappa |
| Application | / |
| Specificity | Detects IL-36R |
| Gene | IL-36R |
| Other Names | IL-1Rrp2, IL1RL2, IL1R-rp2, IL1RRP2 |
| Gene ID | 8808 (human) |
| Background | Recibokibart is a novel anti-IL-36R (interleukin-36 receptor) humanized monoclonal antibody that rapidly alleviates the inflammatory response by specifically blocking IL-36R activation and inhibiting downstream pro-inflammatory signaling pathways. It has shown rapid and long-lasting results in early clinical studies, improving skin symptoms significantly after a single dose and lasting for several weeks. Based on its unique mechanism of action, this drug has not only made breakthroughs in the treatment of specific types of psoriasis, but has also been found to have potential therapeutic value for other complex inflammatory skin diseases driven by neutrophils, and has been used in the treatment of psoriasis, especially in critically ill patients where traditional therapies have limited efficacy, the therapeutic promise of synergy is demonstrated. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
